Guía de Práctica Clínica para el Manejo de Pacientes
con Trastornos de Ansiedad en Atención Primaria.

V. resumida | Info pacientes | Consulta rápida

  1. Introducción
  2. Alcance y objetivos
  3. Metodología de la guía
  4. Definición, manifestaciones clínicas y clasificaciones
  5. Diagnóstico de la ansiedad
  6. Tratamiento de la ansiedad
  7. Información / comunicación al paciente
  8. Estrategias diagnósticas y terapéuticas
  9. Difusión e implementación
  10. Recomendaciones de investigación futura
  11. Bibliografía

Abre nueva ventana: Bibliografia en versión pdf
Descargar GPC Ansiedad Abre nueva ventana(1,45 Mb)

Bibliografía

  1. 1. Grupo de trabajo sobre GPC. Elaboración de Guías de Práctica Clínica en el Sistema Nacional de Salud. Manual Metodológico. Madrid. Plan Nacional para el SNS del MSC. Instituto Aragonés de Ciencias de la salud-I+CS; 2006. Guías de Práctica Clínica en el SNS: I+CS Nº 2006/0I.
  2. 2. Guía de Salud Mental en Atención Primaria. Grupo de Trabajo de Salud Mental PAPPS, 2001.
  3. 3. Informe del Estado de Salud de la Población de la Comunidad de Madrid 2004. Dirección General de Salud Pública y Alimentación. Consejería de Sanidad y Consumo. Comunidad de Madrid. 2005.
  4. 4. Estrategia en Salud Mental del Sistema Nacional de Salud. 2006. Ministerio de Sanidad y Consumo. [documento Internet]. [Acceso 20 marzo 2007].
    Disponible en: http://www.msc.es/organizacion/sns/planCalidadSNS/pdf/excelencia/
    salud_mental/ESTRATEGIA_SALUD_MENTAL_SNS_PAG_WEB.pdf
    Abre nueva ventana
  5. 5. Ormel J. et al. Common mental disorders and disability across cultures. Results from the WHO collaborative study on psychological problems in general health care. JAMA. 1994; 272:1741-1748.
  6. 6. Cortes J.A. et al. La prevalencia de malestar psíquico en atención primaria y su relación con el grado de frecuentación de las consultas. Atención Primaria. 1993; 11:459- 463.
  7. 7. Demertzis KH.et al. Anxiety in primary care. Current Psychiatry Reports. 2006; 8:291- 297.
  8. 8. Kroenke K. et al. Anxiety disorders in primary care: prevalence, impairment, comorbidity and detection. Annals of Internal Medicine. 2007; 146:317-325.
  9. 9. Martín Pérez C. et al. Prevalencia de psicopatías en un centro de salud rural. Atención primaria. 2003; 31:39-46.
  10. 10. Chocrón Bentata L et al. Prevalencia de psicopatología en un centro de atención primaria. Atención Primaria.1995; 16:586-593.
  11. 11. The European Opinion Research Group. The Mental Health Status of the European Population. Eurobarometer 58.2. [documento Internet]. Brussels. 2003. [Acceso 10 de enero de 2007]. Disponible en http://ec.europa.eu/health/ph_determinants/life_style/mental_eurobaro.pdf Abre nueva ventana
  12. 12. Somers JM, Goldner EM, Waraich P, Hsu L. Prevalence and Incidence Studies of Anxiety Disorders: A Systematic Review of the Literature. Canadian Journal Psychiatry. 2006; 51:100–113.
  13. 13. Martínez Álvarez J.M. et al. Estudio de morbilidad psiquiátrica en la población atendida en el Centro de Salud de Basauri. Atención Primaria. 1993; 11:127-132.
  14. 14. Caballero Martínez L. et al. Prevalencia de los trastornos psiquiátricos en atención primaria usando el cuestionario PRIME-MD. Atención Primaria. 1999; 23:275-279.
  15. 15. Haro JM, Palacín C, Vilagut G, Martínez M, Bernal M, Luque I, Codony M, Dolz M, Alonso J y el Grupo ESEMeD-España. Prevalencia de los trastornos mentales y factores asociados: resultados del estudio ESEMeD-España. Medicina Clínica (Barc). 2006; 126(12):445-51.
  16. 16. Roy-Byrne PP. Generalized anxiety and mixed anxiety-depression: association with disability and health care utilization. The Journal of Clinical Psychiatry. 1996; 57 (Supl 7): 86-91.
  17. 17. López-Torres J, Escobar F, Fernández C, González L, Urbistondo L, Requeza M. Trastornos mentales y utilización de las consultas de medicina general. Atención Primaria. 1992; 10:665-70.
  18. 18. Shear MK, Schulberg HC. Anxiety disorders in primary care. Bull Menninger Clin. 1995; 59:73-85..
  19. 19. Jenkins R, Goldberg D, Kiima D, Mayeya J, Mayeya P, Mbatia J, et al. Classification in primary care: experience with current diagnostic systems. Psychopathology. 2002; 35:127-31.
  20. 20. Bowers PJ. Selections from current literature: psychiatric disorders in primary care. J Fam Pract. 1993; 10: 231-237.
  21. 21. Sherbourne CD, Jackson CA, Meredith LS, Camp P, Wells KB. Prevalence of comorbid anxiety disorders in primary care outpatients. Arch Fam Med. 1996; 5: 27-357.
  22. 22. Vega AT, Larrañaga M,Zurriaga O,Gil M,Urtiaga M, Calabuig J. Trastornos de ansiedad. Variabilidad y condicionantes de la actitud terapéutica de los médicos de Atención Primaria. Atención Primaria. 1999; 24:569-78.
  23. 23. Hodges B,Inch C,Silver I. Improving the psychiatric knowledge, skills, and attitudes of primary care physicians, 1950-2000: a review. Am J Psychiatry. 2001; 158:1579-86.
  24. 24. Gene J, Sanjosé S, Torruella J, Godoy F, Leal C, Olmedilla A, et al. Valoración de la motivación de los médicos de Atención Primaria por la Salud Mental. Atención Primaria. 1985; 2:289-92.
  25. 25. Vicente V, Bedía C, Aragón T, Palmer R, Munárriz M. Opiniones de los profesionales de atención primaria sobre los enfermos mentales y la asistencia psiquiátrica. Atención Primaria. 1992; 9:197-202.
  26. 26. Muñoz BA, Pérez PS, Pérez-Vega L. Actitudes de médicos y enfermeros hacia la integración de la salud mental en Atención Primaria. Atención Primaria. 1993; 11:134-6.
  27. 27. Beltran M, Salleras N, Camps C, Solanas P, Igual E, García-Oria M. Abordaje de los problemas de salud mental desde atención primaria. Relación con los servicios de apoyo especializados. Atención Primaria. 2001; 28:39-45.
  28. 28. Latorre Postigo JM, et al. Percepción de la demanda y necesidades de formación en salud mental de los médicos de atención primaria. Atención Primaria. 2005; 36(2):85-92.
  29. 29. Katon W. et al. Anxiety disorders: efficient screening is the first step in improving outcomes. Annals of Internal Medicine. 2007; 146:390-391.
  30. 30. López-Ibor JJ, Valdés M, editores. DMS-IV-TR-AP. Manual diagnóstico y estadístico de los trastornos mentales. Texto revisado. Atención Primaria. Barcelona: Masson; 2004.
  31. 31. Marrs JA. Stress, Fears and Phobias: The Impact of Anxiety. Clinical Journal of Oncology Nursing. 2006; 10(3): 319-22.
  32. 32. Lobo A, Campos R. Factores etiopatogénicos. En :Trastornos de ansiedad en atención primaria. Madrid: Editorial EMISA; 1997. p.41-76.
  33. 33. Tyrer P, Baldwin D. Generalised anxiety disorder. Lancet. 2006; 368: 2156–66.
  34. 34. McIntosh A, Cohen A, Turnbull N, Esmonde L, Dennis P, Eatock J et al. Clinical Guidelines and Evidence Review for Panic Disorder and Generalised Anxiety Disorder. Sheffield:University of Sheffield/London. National Collaborating Centre for Primary Care. 2004; pg.14.
  35. 35. Gratacòs M, Nadal M, Martín-Santos R, Pujana MA, Gago J, Peral B et al. A Polymorphic Genomic Duplication on Human Chromosome 15 Is a Susceptibility Factor for Panic and Phobic Disorders. Cell. 2001; Vol. 106: 367–379.
  36. 36. Hettema JM, Neale MC, Kendler KS . A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am J Psychiatry. 2001; 158(10):1568-78.
  37. 37. Allgulander C. Generalized anxiety disorder: What are we missing?. European Neuropsychopharmacology. 2006; 16: 101-108.
  38. 38. Gross C, Hen R. The development origins of anxiety. Nature Reviews Neuroscience. 2005; 5: 545-552.
  39. 39. Battaglia M, Ogliari A. Anxiety and panic: from human studies to animal research and back. Neuroscience and Biobehavioral Reviews.2005;29:169-179.
  40. 40. López-Ibor JJ, Valdés M, editores. DMS-IV-TR. Manual diagnóstico y estadístico de los trastornos mentales. Texto revisado. Barcelona: Masson; 2002.
  41. 41. OMS. CIE 10: Trastornos mentales y del comportamiento. Descripciones clínicas y pautas para el diagnóstico. Madrid: MEDITOR, 1992.
  42. 42. Comité Internacional de Clasificación de la WONCA. Clasificación Internacional de la Atención Primaria: CIAP-2. Barcelona: Masson; 1999.
  43. 43. Balon R. Mood, Anxiety and Physical Illness: Body and Mind or Mind and Body?. Dep & Anxiety. 2006; 23:377-388.
  44. 44. Pascual JC, Castaño J, Espluga N, Díaz B, García-Ribera C, Bulbena A. Enfermedades somáticas en pacientes con trastornos de ansiedad. Med Clin (Barc). 2008;130(8):281-5.
  45. 45. Härter M, Conway K, Merikangas K. Associations between anxiety disorders and physical illness. European Archives of Psychiatry and Clinical Neuroscience. 2003; 253:313-20.
  46. 46. Sareen J, Jacobi F, Cox BJ, Belik SL, Clara I, Stein MB. Disability and poor quality of life associated with comorbid anxiety disorders and physical conditions. Archives of Internal Medicine. 2006;166:2109-16.
  47. 47. Bulbena A, Gago, J, Martín Santos R, Porta, M, Dasquens J, Berrios GE. Anxiety disorder & Joint laxity: A definitive link. Neurology, Psychiatry and Brain Research. 2004; 11:137-140.
  48. 48. García Campayo J, Alda M. Salud mental e inmigración. Barcelona: Edikamed; 2005.
  49. 49. Leff J. Cultural influence on psychiatry. Curr Opin Psychiatry. 1994; 7:197-201.
  50. 50. Bulbena A, Martín Santos R, Mateo A, Gelabert A. Koro syndrome: primer caso en España. Medicina Clínica (Barc). 1990; 13:36.
  51. 51. Caballero L, Iruela L, Muñoz PE, Baca E. A propósito de un caso de Koro descrito en España. Medicina Clinica. 1990; 95: 519.
  52. 52. Salman E, Carrasco JL, Liebowitz M, Díaz M, Prieto R, Jusino C, et al. Los “ataques de nervios”: Un estudio de caracterización diagnóstica. Actas Luso-Esp Neurol Psiquiatr . 1997; 25: 285-89.
  53. 53. Hernández Monsalve M. La entrevista clínica en Atención Primaria. En: Fernández Liria A, Romero Hidalgo A, editors. Salud Mental en Atención Primaria. Madrid: IDEPSA; 1989. p. 1-49.
  54. 54. Tizón García JL. Components psicològics de la pràctica mèdica: una perspectiva. Barcelona: Acadèmia de Cièncias mèdiques de Catalaunya i e Balears; 1987.
  55. 55. Borrel Carrión F. Manual de entrevista clínica. Barcelona. Doyma; 1989.
  56. 56. Gradillas V. Arte y técnica de la entrevista psiquiátrica. Barcelona. JIMS; 1992.
  57. 57. Golberg D, Huxley P. Técnicas de entrevista en atención primaria. En: Golberg D, Huxley P, editores. Enfermedad mental en la comunidad. Madrid: Nieva; 1990. p.171-180.
  58. 58. Stern T, Herman J, Slavin P. Psiquiatría en la consulta de atención primaria: guía práctica. Massachusetts general Hospital. 2005.
  59. 59. Vázquez-Barquero J.L. et all. Psiquiatría en Atención Primaria. Madrid: Grupo Aula Médica, SA; 1998.
  60. 60. Dupuy L, Losasso A. Entrevista clínica: algunas herramientas. Archivos de Medicina Familiar y General. 2004; 1(1):1-15.
  61. 61. Pascual P, Induráin S. Cómo mejorar nuestras entrevistas clínicas. Anales del Sistema Sanitario de Navarra. 2001; Vol 24; Suplem 2:15-21.
  62. 62. Lobo A, Montón C, Campos R, García-Campayo J, Pérez Echevarría MJ y el GZEMPP. Detección de morbilidad psíquica en la práctica médica. El nuevo instrumento EADG. Zaragoza: Luzán SA Ed; 1993.
  63. 63. Chamorro García L. Guía de manejo de los trastornos mentales en Atención Primaria. Barcelona: Ars Medica. Psiquiatría editores S.L; 2004.
  64. 64. Bulbena A, Ibarra N, Ballesteros J y Gago J. Instrumentos de evaluación de los trastornos mentales en atención primaria. En: Vázquez Barquero JL. Psiquiatría en atención primaria. 2ª ed. Grupo aula médica S.L.; 2008. p.107-125.
  65. 65. Badía X, Alonso J. Medidas de bienestar psicológico y salud mental. En: Badía X, Alonso J, editores. La medida de la salud. Guía de escalas de medición en español. Barcelona; 2007. p.49-88.
  66. 66. Montón C, Pérez Echeverría MI, Campos R y cols.: Escalas de ansiedad y depresión de Goldberg: una guía de entrevista eficaz para la detección del malestar psíquico. Atención Primaria. 1993; 12(6):345-9.
  67. 67. Quintana JM, Padierna A, Esteban C, Arostegui I, Bilbao A, Ruiz I. Evaluation of the psychometric characteristics of the Spanish version of the Hospital Anxiety and Depression Scale. Acta Psychiatrica Scandinavica. 2003; 107(3):216-21.
  68. 68. Runkewitz K, Kirchmann H, Strauss B. Anxiety and depression in primary care patients: predictors of symptom severity and developmental correlates. Journal Psychosomatic Research. 2006; 60(5):445-53.
  69. 69. Bulbena A, Bobes J, Luque A, Dal-Ré R, Ballesteros J, Ibarra N y el Grupo de Validación en Español de Escalas Psicométricas (GVEEP): Validación de las versiones en español de la Clinical Anxiety Scale y del Physician Questionnaire para la evaluación de los trastornos de ansiedad. Medicina Clínica (Barc). 2003; 121(10):367-374.
  70. 70. Canadian Psychiatric Association, Clinical Practice Guidelines. Management of Anxiety Disorders. The Canadian Journal of Psychiatry, 2006.
  71. 71. Fernández Liria A, Rodríguez Vega B. La práctica de la psicoterapia. Bilbao: Desclée; 2001.
  72. 72. Vélez Noguera JL. Enfoque de la salud mental en Atención Primaria. Barcelona: Organon Española S.A; 1991.
  73. 73. Ridel-Heller SG, Matschinger H, Angermeyer MC. Mental disorders –who and what might help? Help-seeking and treatment preferences of the lay public. Social Psychiatry and Psychiatric Epidemiology. 2005; 40:167-74.
  74. 74. Lobo A, Campos R et al. Los trastornos de ansiedad en Atención Primaria. 1ª ed. Madrid: EMISA; 1997.
  75. 75. Álvarez Gálvez E. Diagnóstico y tratamiento de los trastornos de ansiedad. Centro de Salud. 1998; 6(2): 82-93.
  76. 76. Caro Gabalda I. Manual teórico-práctico de Psicoterapias Cognitivas. Bilbao: Desclée de Brouwer; 2007.
  77. 77. García Ramos J, Gallego Rodríguez J.M. Psicoterapias en atención primaria. Formación Médica Continuada. 2003; 10 (7): 508-13.
  78. 78. Bateman A, Brown D, Pedder J. Introducción a la Psicoterapia. Manual de la teoría y técnica psicodinámicas. Barcelona: Ed. Albesa S.L.; 2005.
  79. 79. INSALUD. Protocolos de Salud Mental en Atención Primaria: Ansiedad, Insomnio y Depresión. Madrid: Área 1. Atención Primaria, 1997.
  80. 80. National Institute for Health and Clinical Excellence (NICE). Clinical Guideline 22. Anxiety: management of anxiety (panic disorder, with or without agoraphobia, and generalised anxiety disorder) in adults in primary, secondary and community care. London: National Institute for Health and Clinical Excellence, 2004.
  81. 81. National Institute for Health and Clinical Excellence (NICE). Clinical Guideline 22 (amended). Anxiety: management of anxiety (panic disorder, with or without agoraphobia, and generalised anxiety disorder) in adults in primary, secondary and community care. London: National Institute for Health and Clinical Excellence, 2007.
  82. 82. MOH Clinical Practice Guidelines 7. Anxiety Disorders. Singapore: Ministry of Health, 2003.
  83. 83. Linden M, Zubraegel D, Baer T, Franke U, Schlattman P. Efficacy of Cognitive Beaviour Therapy in Generalized Anxiety Disorders. Psychotherapy and Psychosomatics; 2005; 74:36-42.
  84. 84. Dugas MJ, Ladouceur R, Léger E, Freeston MH, Langlois F, Provencher MD, Boisvert JM. Group cognitive-behavioral therapy for generalized anxiety disorder: treatment outcome and long-term follow-up. Journal of Consulting and Clinical Psychology. 2003; 71(4):821-5.
  85. 85. Borkovec TD, Newman MG, Pincus AL, Lytle R. A component analysis of cognitivebehavioral therapy for generalized anxiety disorder and the role of interpersonal problems. Journal of Consulting and Clinical Psychology. 2002; 70(2):288-98.
  86. 86. Hunot V, Churchill R, Silva de Lima M, Teixeira V. Terapias psicológicas para el trastorno de ansiedad generalizada (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2007 Número 2. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com Abre nueva ventana. (Traducida de The Cochrane Library, 2007 Issue 2. Chichester, UK: John Wiley & Sons, Ltd.).
  87. 87. BMJ Clinical Evidence (base de datos en Internet). London: British Medical Journal; 2006-. Gale C. Generalised anxiety disorder, [actualizada en febrero de 2006; acceso 24 de mayo de 2007]; Disponible en: http://www.clinicalevidence.bmj/ceweb/index.jsp Abre nueva ventana
  88. 88. Durham RC, Chambers JA, Power KG, Sharp DM, Macdonald RR, Major KA, et al. Long-term outcome of cognitive behaviour therapy clinical trials in central Scotland. Health Technology Assessment. 2005; 9(42).
  89. 89. Durham RC, Chambers JA, MacDonald RR, Power KG, Major K. Does cognitive-behavioural therapy influence the long-term outcome of generalized anxiety disorder? An 8-14 year follow-up of two clinical trials. Psychological Medicine. 2003; 33:499-509.
  90. 90. Price D, Beck A, Nimmer C, Bensen S. The Treatment Of Anxiety Disorders In A Primary Care HMO Setting. Psychiatric Quarterly. 2000; 71(1):31-45.
  91. 91. Stanley M A, Hopko D R, Diefenbach G J, Bourland S L, Rodriguez H, Wagener P. Cognitive–Behavior Therapy for Late-Life Generalized Anxiety Disorder in Primary Care: Preliminary Findings. American Journal Geriatric Psychiatry. 2003; 1(1):92-6.
  92. 92. van Boeijen CA, van Oppen P, van Balkom A J, Visser S, Kempe P T, Blankenstein N, van Dyck R. Treatment of anxiety disorders in primary care practice: a randomised controlled trial. British Journal of General Practice. 2005; 55(519):763-9.
  93. 93. Burgos Varo ML, Ortiz Fernández MD, Muñoz Cobos F, Vega Gutiérrez P, Bordallo Aragón R. Intervención grupal en los trastornos de ansiedad en Atención Primaria: técnicas de relajación y cognitivo-conductuales. SEMERGEN. 2006; 32(5):205-210.
  94. 94. Tello Bernabé ME, Téllez Arévalo A, Ruiz Serrano A, de Frutos Martín MA, Elcano Alfaro R. Técnicas grupales y relajación en el tratamiento de algunos subtipos de ansiedad: un estudio de intervención controlado no aleatorio. Atención Primaria, 1997; 19:67-71.
  95. 95. van Balkom A J, Bakker A, Spinhoven P, Blaauw B M, Smeenk S, Ruesink B. A metaanalysis of the treatment of panic disorder with or without agoraphobia: a comparison of psychopharmacological, cognitive-behavioral, and combination treatments. Journal of Nervous and Mental Disease. 1997; 185:510-516.
  96. 96. Bakker A, van Balkom A J, Spinhoven P, Blaauw B M, van Dyck R. Follow-up on the treatment of panic disorder with or without agoraphobia: a quantitative review. Journal of Nervous and Mental Disease. 1998; 186:414-419.
  97. 97. Abbass AA, Hancock JT, Henderson J, Kisely S. Psicoterapias psicodinámicas a corto plazo para trastornos mentales frecuentes. (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2007 Número 2. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com. (Traducida de The Cochrane Library, 2007 Issue 2. Chichester, UK: John Wiley & Sons, Ltd.).
  98. 98. BMJ Clinical Evidence (base de datos en Internet). London: British Medical Journal; 2006-. Kumar S, Oakley-Browne M. Panic disorder [actualizada en mayo de 2006; acceso 17 de junio de 2007]; Disponible en: http://www.clinicalevidence.bmj/ceweb/index.jsp Abre nueva ventana
  99. 99. Stuart GL, Treat TA, Wade WA. Effectiveness of an empirically based treatment for panic disorder delivered in a service clinic setting: 1-year follow-up. Journal of Consulting and Clinical Psychology. 2000; 68(3):506-12.
  100. 100. Bruce TJ, Spiegel DA, Hegel MT. Cognitive-behavioral therapy helps prevent relapse and recurrence of panic disorder following alprazolam discontinuation: a long-term follow-up of the Peoria and Dartmouth studies. Journal of Consulting and Clinical Psychology. 1999; 67(1):151-6.ç
  101. 101. Hunt C, Andrews G. Long-term outcome of panic disorder and social phobia. Journal of Anxiety Disorders. 1998; 12(4):395-406.
  102. 102. Mitte K. A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobia. Journal of Affective Disorders. 2005; 88:27–45.
  103. 103. The Swedish Council on Technology Assessment in Health Care. Treatment of Anxiety Disorders. A Systematic Review. Summary and Conclusions. Sweeden; November, 2005.
  104. 104. Austin D, Blashki G, Barton D, Klein B. Managing panic disorder in general practice. Australian Family Physician. 2005; 34(79): 563-571.
  105. 105. Sharp D M, Power K G, Swanson V. Reducing therapist contact in cognitive behaviour therapy for panic disorder and agoraphobia in primary care: global measures of outcome in a randomised controlled trial. British Journal of General Practice. 2000; 50:963-968.
  106. 106. Sharp DM, Power KG, Swanson V. A Comparison of the Efficacy and Acceptability of Group versus Individual Cognitive Behaviour Therapy in the Treatment of Panic Disorder and Agoraphobia in Primary Care. Clinical Psychology and Psychotherapy. 2004; 1(2):73–82.
  107. 107. Nadiga D N, Hensley P L, Uhlenhuth E H. Review of the long-term effectiveness of cognitive behavioural therapy compared to medications in panic disorder. Depression and anxiety. 2003; 17:58–64.
  108. 108. Galaverni E, Pozo Navarro P, Bellini M. A survey of panic symptoms in a primary care setting. Atención Primaria. 2005 15; 36(6):312-6.
  109. 109. Katerndahl D, Realini JP. Where do panic attack sufferers seek care?. J Fam Pract. 1995; 40: 237-43.
  110. 110. Katerndahl D A, Realini, J P. Patients with Panic Attacks Seeking Care from Family Physicians Compared with Those Seeking Care From Psychiatrists. The Journal of Nervous and Mental Disease. 1998; 186(4): 249-250.
  111. 111. Katerndahl D. Panic-related outcomes in patients with a personal physician. Family medical. 2003; 35(3): 209-14.
  112. 112. Merritt TC. Recognition and acute management of patients with panic attacks in the emergency department. Emergency Medicine Clinics of North America. 2000; 18(2):289-300.
  113. 113. De la Gándara Martín J J, García Moja LC. Vademécum de psicoterapias, vol 1. Técnicas de terapia de conducta y técnicas de relajación. Madrid:Ed. Luzan, S.A.; 2000.
  114. 114. De la Gándara Martín J J, García Moja LC. Vademécum de psicoterapias, vol 2. Técnicas de terapia cognitiva y cognitivo- conductual. Madrid:Ed. Luzan, S.A.; 2000.
  115. 115. García-Campayo J. Hidalgo Campos I. Orozco González F. Psicoterapia de resolución de problemas en atención primaria. Barcelona: Grupo Ars XXI de Comunicación, SL; 2006.
  116. 116. Mynor-Wallis LM. Problem-solving treatment: evidence for effectiveness and feasibility in primary care. In J Psychiatry Med. 1996; 26:249-262.
  117. 117. Güemes I, Ballesteros J. La eficacia de las psicoterapias breves estructuradas en el tratamiento de los trastornos afectivos en la atención ambulatoria. Norte de Salud Mental. 2006; 25:15-25.
  118. 118. Diéguez M, Rodríguez V, Fernández L. Psicoterapia en Atención Primaria: Consejo interpersonal para la depresión. MEDIFAM. 2001; 11: 156-162.
  119. 119. González M, Revuelta C, Rodríguez-Arias JL. Terapia Familiar Breve: evaluación de resultados y estudio de seguimiento. Congreso de la Asociación Española para la Investigación y el Desarrollo de la Terapia Familiar [Póster]; mayo 1998, Sevilla, España.
  120. 120. Real Pérez M, Rodríguez-Arias Palomo JL, Cagigas Viadero J, Aparicio Sanz MM, Real Pérez MA. Terapia familiar breve: una opción para el tratamiento de los trastornos somatomorfos en Atención Primaria. Atención Primaria. 1996 Mar 15; 17(4): 241-6.
  121. 121. Rodríguez-Arias JL, Fontecilla G, Ramos M. Evaluación de resultados en Terapia Familiar Breve. XIV Jornadas Nacionales de Terapia Familiar. 1993; Santiago de Compostela, España.
  122. 122. Casacalenda N, Boulenger J P. Pharmacologic treatments effective in both generalized anxiety disorder and major depressive disorder: clinical and theoretical implications. Canadian Journal of Psychiatry. 1998; 43(7): 722-730.
  123. 123. Kapczinski F, Lima MS, Souza, JS, Schmitt, R. Antidepresivos para el trastorno de ansiedad generalizada (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2007 Número 2. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com. (Traducida de The Cochrane Library, 2007 Issue 2. Chichester, UK: John Wiley & Sons, Ltd.).
  124. 124. Kim TS, Pae CU, Yoon SJ, Bahk WM, Jun TY, Rhee WI, Chae JH. Comparison of venlafaxine extended release versus paroxetine for treatment of patients with generalized anxiety disorder. Psychiatry Clin Neurosci. 2006 Jun; (3):347-51.
  125. 125. Brawman-Mintzer O, Knapp RG, Rynn M, Carter RE, Rickels K. Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. The Journal of Clinical Psychiatry. 2006; 67(6):874-81.
  126. 126. Koponen H, Allgulander C, Erickson J, Dunayevich E, Pritchett Y, Detke MJ, Ball SG, Russell JM. Efficacy of Duloxetine for the Treatment of Generalized Anxiety Disorder: Implications for Primary Care Physicians. Prim Care Companion J Clin Psychiatry. 2007; 9(2):100-107.
  127. 127. Endicott J, Russell JM, Raskin J, Detke MJ, Erickson J, Ball SG, Marciniak M, Swindle RW. Duloxetine treatment for role functioning improvement in generalized anxiety disorder: three independent studies. The Journal of Clinical Psychiatry. 2007; 68(5):806.
  128. 128. Hartford J, Kornstein S, Liebowitz M, Pigott T, Russell J, Detke M, Walker D, Ball S, Dunayevich E, Dinkel J, Erickson J. Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. Int Clin Psychopharmacol. 2007; 22(3):167-74.
  129. 129. US Food and Drug Administration [sede Web]. Antidepressant Use in Children, Adolescents, and Adults. [acceso 1 de octubre de 2007]. Disponible en http://www.fda.gov/cder/drug/antidepressants/default.htm Abre nueva ventana
  130. 130. US Food and Drug Administration [sede Web]. FDA Public Health Advisory Paroxetine. [acceso 20 de diciembre de 2007]. Disponible en: http://www.fda.gov/cder/drug/advisory/paroxetine200512.htm Abre nueva ventana
  131. 131. Gentile S. Serotonin reuptake inhibitor-induced perinatal complications. Paediatric Drugs. 2007; 9 (2):97-106.
  132. 132. Davis RL, Rubanowice D, McPhillips H, Raebel MA, Andrade SE, Smith D, Yood MU, Platt R. HMO Research Network Center for Education, Research in Therapeutics. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiology and Drug Safety 2007; 16(10):1086-94.
  133. 133. Looper KJ. Potential medical and surgical complications of serotonergic antidepressant medications. Psychosomatics. 2007; 48(1):1-9.
  134. 134. Moses-Kolko EL, Bogen D, Perel J, Bregar A, Uhl K, Levin B, Wisner KL. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. Journal of the American Medical Association. 2005; 18; 293(19):2372-83.
  135. 135. Lattimore KA, Donn SM, Kaciroti N, Kemper AR, Neal CR Jr, Vazquez DM. Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-analysis. Journal of Perinatology. 2005; 25(9):595-604.
  136. 136. Mejías C, Rodríguez-Pinilla E, Fernández Martín P, Martínez-Frías ML. Adverse effects of selective serotonin reuptake inhibitors use during the third trimester of pregnancy and prevention guidelines. Medicina Clínica (Barc). 2007 Apr 21; 128(15):584-9.
  137. 137. Baldwin DS, Huusom AK, Maehlum E. Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study. Evid Based Ment Health. 2007; 10(2):45.
  138. 138. Rickels K, Rynn M, Iyengar M, Duff D. Remission of generalized anxiety disorder: a review of the paroxetine clinical trials database. The Journal of Clinical Psychiatry. 2006; 67(1):41-7.
  139. 139. Stocchi F, Nordera G, Jokinen RH, Lepola UM, Hewett K, Bryson H, Iyengar MK. Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J Clin Psychiatry. 2003; 64(3):250-8.
  140. 140. Allgulander C, Florea I, Huusom AK. Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol. 2006; 9(5):495-505.
  141. 141. (MHRA) Medicines and Healthcare products Regulatory Agency. [sede Web]. Press releases updated product information for Efexor (venlafaxine). 2007 [acceso 29 de octubre de 2007]. Disponible en: http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&useSecondary
    =true&ssDocName=CON2023843&ssTargetNodeId=389
    Abre nueva ventana
  142. 142. Medicamentos autorizados en España (uso humano). [sede Web]*. Agencia Española de Medicamentos y Productos Sanitarios AEMPS; 2007 [acceso 20 diciembre de 2007]. Disponible en: https://sinaem4.agemed.es/consaem/fichasTecnicas.do?metodo=detalleForm Abre nueva ventana
  143. 143. Iqbal MM, Sobhan T, Ryals T. Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant. Psychiatr Serv. 2002; 53(1):39-49.
  144. 144. Lin AE, Peller AJ, Westgate MN, Houde K, Franz A, Holmes LB. Clonazepam use in pregnancy and the risk of malformations. Birth Defects Research. Part A, Clinical Molecular Teratology. 2004; 70(8):534-6.
  145. 145. Mitte K, Noack P, Steil R, Hautzinger M. A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder. Journal of Clinical Psychopharmacology. 2005; 25(2):141-150.
  146. 146. Malgorn G, Leboucher B, Harry P, Turcant A, Catala L, Giniès JL. Benzodiazepine poisoning in a neonate: clinical and toxicokinetic evaluation following enterodialysis with activated charcoal. Archives de Pédiatrie. 2004; 11(7):819-21.
  147. 147. Swortfiguer D, Cissoko H, Giraudeau B, Jonville-Béra AP, Bensouda L, Autret-Leca E. Neonatal consequences of benzodiazepines used during the last month of pregnancy. Archives de pédiatrie. 2005; 12(9):1327-31.
  148. 148. Murray KL, Miller KM, Pearson DL. Neonatal withdrawal syndrome following in utero exposure to paroxetine, clonazepam and olanzapine. Journal of perinatology: official journal of the Californian Perinatal Association. 2007; 27(8):517-8.
  149. 149. García-Algar O, López-Vílchez MA, Martín I, Mur A, Pellegrini M, Pacifici R, Rossi S, Pichini S. Confirmation of gestational exposure to alprazolam by analysis of biological matrices in a newborn with neonatal sepsis. Clinical Toxicology (Philadelphia, Pa.). 2007; 45(3):295-8.
  150. 150. Chessick CA, Allen MH, Thase ME, Batista Miralha da Cunha ABC, Kapczinski FFK, de Lima MSML, dos Santos Souza JJSS. Azapironas para el trastorno de ansiedad generalizada (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2007 Número 2. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com. (Traducida de The Cochrane Library, 2007 Issue 2. Chichester, UK: John Wiley & Sons, Ltd.).
  151. 151. Rickels K, Pollack MH, Feltner DE, Lydiard RB, Zimbroff DL, Bielski RJ, Tobias K, Brock JD, Zornberg GL, Pande AC. Pregabalin for Treatment of Generalized Anxiety Disorder. A 4-Week, Multicenter, Double-blind, Placebo-Controlled Trial of Pregabalin and Alprazolam. Archives of General Psychiatry. 2005; 62:1022-1030.
  152. 152. Bech P. Dose-response relationship of pregabalin in patients with generalized anxiety disorder. A pooled analysis of four placebo-controlled trials. Pharmacopsychiatry. 2007; 40(4):163-8.
  153. 153. Montgomery SA, Tobias K, Zornberg GL, Kasper S, Pande AC. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. Evidence Based Mental Health. 2007; 10(1):23.
  154. 154. Pohl RB, Feltner DE, Fieve RR, Pande AC. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. Journal of Clinical Psychopharmacology. 2005; 25(2):151-8.
  155. 155. Simon NM, Hoge EA, Fischmann D, Worthington JJ, Christian KM, Kinrys G, Pollack MH. An open-label trial of risperidone augmentation for refractory anxiety disorders. J Clin Psychiatry. 2006; 67(3):381-5.
  156. 156. Snyderman SH, Rynn MA, Rickels K. Open-label pilot study of ziprasidone for refractory generalized anxiety disorder. Clin Psychopharmacol. 2005 Oct;25(5):497-9.
  157. 157. Pollack MH, Roy-Byrne PP, Van Ameringen M, Snyder H, Brown C, Ondrasik J, Rickels K. The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study. Journal of Clinical Psychopharmacology. 2005; 66(11):1401-8.
  158. 158. Mathew SJ, Amiel JM, Coplan JD, Fitterling HA, Sackeim HA, Gorman JM. Open-label trial of riluzole in generalized anxiety disorder. Am J Psychiatry. 2005; 162(12):2379- 81.
  159. 159. Naukkarinen H, Raassina R, Penttinen J, Ahokas A, Jokinen R, Koponen H, Lepola U, Kanerva H, Lehtonen L, Pohjalainen T, Partanen A, Mäki-Ikola O, Rouru J; Deramciclane Dose-Finding Study Group. Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study. European Neuropsychopharmacology. 2005; 15(6):617-23. Epub 2005 Jun 9.
  160. 160. Sáiz Ruiz J, Ibáñez Cuadrado A, Montes Rodríguez JM. Trastorno de angustia. Crisis de pánico y agorafobia en atención primaria. Barcelona: MASSON S.A.; 2001.
  161. 161. Marchesi C, Cantoni A, FontC2 S, Giannelli MR, Maggini C. The effect of pharmacotherapy on personality disorders in panic disorder: a one year naturalistic study. J Affect Disord. 2005; 89(1-3):189-94.
  162. 162. Palao Vidal D, Márquez Rowe M, Jódar Ortega I. Guía psiquiátrica en Atención Primaria. SmithKline Beecham; 1996
  163. 163. Boyer W. Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis. International Clinical Psychopharmacology. 1995; 10(1): 45-49.
  164. 164. Wagstaff A J, Cheer S M, Matheson 164. A J, Ormrod D, Goa K L. Paroxetine: an update of its use in psychiatric disorders in adults. Drugs. 2002; 62(4): 655-703.
  165. 165. Pollack MH, Lepola U, Koponen H, Simon NM, Worthington JJ, Emilien G, Tzanis E, Salinas E, Whitaker T, Gao B. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depress Anxiety. 2007; 24(1):1-14.
  166. 166. Fisekovic S, Loga-Zec S. Sertraline and alprazolam in the treatment of panic disorder. Bosn J Basic Med Sci. 2005; 5(2):78-81.
  167. 167. Milrod B, Busch F. Long-term outcome of panic disorder treatment: a review of the Literature. Journal of Nervous and Mental Disease. 1996; 184(12): 723-730.
  168. 168. Ferguson JM, Khan A, Mangano R, Entsuah R, Tzanis E. Relapse prevention of panic disorder in adult outpatient responders to treatment with venlafaxine extended release. The Journal of Clinical Psychiatry. 2007; 68(1):58-68.
  169. 169. Blaya C, Seganfredo AC, Dornelles M, Torres M, Paludo A, Heldt E, Manfro GG. The efficacy of milnacipran in panic disorder: an open trial. Int Clin Psychopharmacol. 2007; 22(3):153-8.
  170. 170. Sheehan DV, Sheehan KH, Raj BA. The speed of onset of action of alprazolam- XR compared to alprazolam-CT in panic disorder. Psychopharmacol Bull. 2007; 40(2):63-81.
  171. 171. Uhlenhuth EH, Starcevic V, Qualls C, Antal EJ, Matuzas W, Javaid JI, Barnhill J. Abrupt discontinuation of alprazolam and cognitive style in patients with panic disorder: early effects on mood, performance, and vital signs. Journal of Clinical Psychopharmacology. 2006; 26(5):519-23.
  172. 172. Sepede G, De Berardis D, Gambi F, Campanella D, La Rovere R, D’Amico M, Cicconetti A, Penna L, Peca S, Carano A, Mancini E, Salerno RM, Ferro FM. Olanzapine augmentation in treatment-resistant panic disorder: a 12-week, fixed-dose, open-label trial. Journal of Clinical Psychopharmacology. 2006; 26(1):45-9.
  173. 173. Uhlenhuth E. H, Matuzas W, Warner Teddy D, Paine Susan, Lydiard R. B, Pollack, M H. Do Antidepressants Selectively Suppress Spontaneous (Unexpected) Panic Attacks? A Replication. Journal of clinical Psychopharmacology. 2000; 20(6): 622-627.
  174. 174. Edna BF, Martin EF, Moser J, Context in the Clinic: How Well Do Cognitive-Behavioral Therapies and Medications Work in Combination?. Biological Psychiatry. 2002; 52:987-997.
  175. 175. Power K G, Simpson R J, Swanson V, Wallace L A. Controlled comparison of pharmacological and psychological treatment of generalized anxiety disorder in primary care. British Journal of General Practice. 1990; 40(336):289–294.
  176. 176. Bernal i Cercós A, Fusté i Vallverdú R, Urbieta Solana R, Montesinos Molina I. Tratamiento de relajación en pacientes con trastornos de ansiedad y somatoformes en atención primaria. Atención Primaria. 1995; 15: 499-504.
  177. 177. Marks IM, Swinson RP, Basaglu M, Kuch K, Nashirvani H, O’Sullivan G, et al. Alprazolam and exposure alone and combined in panic disorder with agoraphobia: A controlled Study in London and Toronto. British Journal Psychiatriy. 1993; 162:776-787.
  178. 178. Cottraux J, Note ID, Cungi C, Legeron P, Heim F, Cheinweiss L, et al. A controlled study of cognitive behavior therapy with buspirone or placebo in panic disorder with agoraphobia. British Journal Psychiatric. 1995; 167:635-641.
  179. 179. Barlow DH, Gorman JM, Shear MK, Woods SW. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. JAMA. 2000; 283:2529–2536.
  180. 180. Furukawa TA, Watanabe N, Churchill R. Psicoterapia combinada más antidepresivos para el trastorno por pánico con o sin agorafobia (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2007 Número 2. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com Abre nueva ventana. (Traducida de The Cochrane Library, 2007 Issue 2. Chichester, UK: John Wiley & Sons, Ltd.).
  181. 181. Craske MG, Golinelli D, Stein MB, Roy-Byrne P, Bystritsky A, Sherbourne C. Does the addition of cognitive behavioural therapy improve panic disorder treatment outcome relative to medication alone in the primary-care setting?. Psychological Medicine. 2005; 35(11): 1645-54.
  182. 182. Roy-Byrne PP, Craske MG, Stein MB. Sullivan G, Bystritsky A, Katon W, Golinelli D, Sherbourne CD. A Randomized Effectiveness Trial of Cognitive-Behavioral Therapy and Medication for Primary Care Panic Disorder. Arch General Psychiatry. 2005; 62(3):290-298.
  183. 183. Sharp DM, Power KG, Simpson RJ, Swanson V, Anstee JA. Global measures of outcome in a controlled comparison of pharmacological and psychological treatment of panic disorder and agoraphobia in primary care. British Journal of General Practice. 1997; 47:150-155.
  184. 184. Bower P, Richards D, Lovell K. The clinical and cost-effectiveness of self-help treatments for anxiety and depressive disorders in primary care: a systematic review. British Journal of General Practice. 2001; 51(471): 838-845.
  185. 185. den Boer P C, Wiersma D, van den Bosch R J. Why is self-help neglected in the treatment of emotional disorders: a meta analysis. Psychological Medicine. 2004; 34(6): 959-971.
  186. 186. van Boeijen C A, van Balkom A J, van Oppen P, Blankenstein N, Cherpanath A, van Dyck R. Efficacy of self-help manuals for anxiety disorders in primary care: a sytematic review. Family Practice. 2005; 22(2): 192-196.
  187. 187. Barlow JH, Ellard DR, Hainsworth JM, Jones FR, Fisher A. A review of self-management interventions for panic disorders, phobias and obsessive-compulsive disorders. Acta Psychiatrica Scandinavica. 2005; 111: 272–285.
  188. 188. Reeves T, Stace JM. Improving patient access and choice: Assisted Bibliotherapy for mild to moderate stress/anxiety in primary care. Journal of Psychiatr and Mental Health Nursing. 2005;12:341-6.
  189. 189. Richards A, M Barkham, J Cahill, et al. PHASE: a randomised, controlled trial of supervised self-help cognitive behavioural therapy in primary care. Br J Gen Pract. 2003; 53(495):764-70.
  190. 190. Wright J et al. A Bibliotherapy Approach to Relapse Prevention in Individuals with Panic Attacks. Journal of Anxiety Disorders. 2000; 14(5):483-499.
  191. 191. Juan Ladrón Y, García-Carrillo B, Oliván Blázquez B, García-Campayo J. Utilidad de la biblioterapia en Atención Primaria. En: García-Campayo J, Hidalgo Campos I, Orozco González F. Psicoterapia de resolución de problemas en atención primaria. 1ª ed. Barcelona: Ars Medica; 2006. p. 107-13.
  192. 192. Febbraro G A. An Investigation into the Effectiveness of Bibliotherapy and Minimal Contact Interventions in the Treatment of Panic Attacks. Journal of Clinical Psychology. 2005; 61(6):763–779.
  193. 193. National Institute for Health and Clinical Excellence (NICE). Computerised cognitive behaviour therapy for depression and anxiety. Review of Technology Appraisal 51. London: National Institute for Health and Clinical Excellence. 2006.
  194. 194. Kaltenthaler E, Brazier J, De Nigris E, Tumur I, Ferriter M, Beverley C, Parry G, Rooney G, Sutcliffe P. Computerised cognitive behaviour therapy for depression and anxiety update: a systematic review and economic evaluation. Health Technology Assessment. 2006; Vol. 10: No. 33.
  195. 195. McCrone P, Knapp M, Proudfoot J, Ryden C, Cavanagh K, Shapiro DA, Ilson S, Gray JA, Goldberg D, Mann A, Marks I, Everitt B, Tylee A. Cost-effectiveness of computerised cognitive-behavioural therapy for anxiety and depression in primary care: randomised controlled trial. Br J Psychiatry. 2004; 185:55-62.
  196. 196. Carlbring P, Bohmann S, Brunt S, Buhrman M, et al. Remote Treatment of Panic Disorder: A Randomized Trial of Internet-Based Cognitive Behavioral Therapy Supplemented with telephone calls. The American Journal of Psychiatry. 2006; 163(12):2119- 2125.
  197. 197. Mihalopoulos C, Kiropoulos L, Shih ST, Gunn J, Blashki G, Meadows G. Exploratory economic analyses of two primary care mental health projects: implications for sustainability. Med J Aust. 2005; 183(10 Suppl):S73-6.
  198. 198. Saeed SA, Bloch RM, Antonacci DJ. Herbal and Dietary Supplements for Treatment of Anxiety Disorders. American Family Physician. 2007; 76(4):549-56.
  199. 199. Pittler MH, Ernst E. Efficacy of kava extract for treating anxiety: systematic review and meta-analysis. Journal of Clinical Psychopharmacol. 2000; 20:84-9.
  200. 200. Pittler MH, Ernst E. Extracto de Kava para el tratamiento de la ansiedad (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2007 Número 2. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com Abre nueva ventana. (Traducida de The Cochrane Library, 2007 Issue 2. Chichester, UK: John Wiley & Sons, Ltd.).
  201. 201. Connor KM, Payne V y Davidson JR. Kava in generalized anxiety disorder: three placebo-controlled trials. International Clinical Psychopharmacology. 2006; 21(5):249-53.
  202. 202. Boerner RJ, Sommer H, Berger W, Kuhn U, et al. Kava-Kava extract LI 150 is as effective as Opipramol and Buspirone in General Anxiety disorder – an 8 week, randomized, double-blind multi-centre clinical trial in 129 out-patients. Phytomedicine. 2003; 10 Suppl 4: 38-49.
  203. 203. Lehrl S. Clinical efficacy of kava extract WSR 1490 in sleep disturbances associated with anxiety disorders - Results of a multicenter, randomized, placebo-controlled, double-blind clinical trial. Journal of Affective Disorders. 2004; 78(2):101–110.
  204. 204. Cairney S, Maruff P, 204. Clough A R, Collie A, Currie J and Currie BJ. Saccade and cognitive impairment associated with kava intoxication. Human Psychopharmacology. 2003; 18(7):525-33. 205.
  205. 205. Barnes J. Quality, efficacy and safety of complementary medicines: fashions, facts and the future. Part II: Efficacy and safety. British Journal of Clininical Pharmacology. 2003; 55(4):331-340.
  206. 206. Center for Food Safety and Applied Nutrition, U.S. Food and Drug Administration. Kava-containing dietary supplements may be associated with severe liver injury. Acceso 19 Octubre de 2007. Disponible en: http://www.cfsan.fda.gov/~dms/addskava.html Abre nueva ventana
  207. 207. ORDEN SCO/190/2004, de 28 de enero, por la que se establece la lista de plantas cuya venta al público queda prohibida o restringida por razón de su toxicidad (B.O.E. 32, de 6 de febrero de 2004). Profesionales Salud Humana. Plantas Medicinales. [sede Web]*. Agencia Española de Medicamentos y Productos Sanitarios AEMPS; 2007 [acceso 20 de diciembre de 2007]. Disponible en: https://sinaem4.agemed.es/consaem/fichasTecnicas.do?metodo=detalleForm Abre nueva ventana
  208. 208. Miyasaka LS, Atallah AN, Soares BGO. Valeriana para los trastornos de ansiedad (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2007 Número 2. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com Abre nueva ventana. (Traducida de The Cochrane Library, 2007 Issue 2. Chichester, UK: John Wiley & Sons, Ltd.).
  209. 209. Miyasaka LS, Atallah AN, Soares BGO. Pasionaria para el trastorno de ansiedad (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2007 Número 2. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com. (Traducida de The Cochrane Library, 2007 Issue 2. Chichester, UK: John Wiley & Sons, Ltd.).
  210. 210. Akhondzadeh S, Naghavi HR, Vazirian M, Shayeganpour A, Rashidi H, Khani M. Passionflower in the treatment of generalized anxiety: a pilot double-blind randomized controlled trial with oxazepam. Journal of Clinical Pharmacy and Therapeutics. 2001; 26:363-367.
  211. 211. Woelk H, Arnoldt K H, Kieser M, Hoerr R. Ginkgo biloba special extract EGb 761 in generalized anxiety disorder and adjustment disorder with anxious mood: A randomized, double-blind, placebo-controlled trial. Journal of Psychiatric Research. 2007; 41(6): 472–480.
  212. 212. Herrera-Arellano A, Jiménez-Ferrer E, Zamilpa A, Morales-Valdéz M, García-Valencia CE, Tortoriello J. Efficacy and tolerability of a standardized herbal product from Galphimia glauca on generalized anxiety disorder. A randomized, double-blind clinical trial controlled with lorazepam. Planta Med. 2007 ;73(8):713-7.
  213. 213. Hanus M, Lafon J, Mathieu M. Double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of a fixed cobination containing two plant extracts (Crataegus oxyacantha and Eschscholtzia californica) and magnesium in mild-to-moderate anxiety disorders. Current Medical Research and Opinion. 2004; 20(1):63-71.
  214. 214. Scottish Intercollegiate Guidelines Network. A guideline developers’ handbook (Publication n° 50) [monografía en Internet]. Edinburgh: SIGN: 2001 [actualizado mayo de 2004; acceso 10 de diciembre de 2006]. Disponible en: http://www.sign.ac.uk/guidelines/fulltext/50/index.html Abre nueva ventana.

 

Última actualización: 27 de noviembre de 2008

Logo del Ministerio de Sanidad y Consumo Logo del Plan de Calidad del Sistema Nacional de SaludLogotipo de la Agencia Laín Entralgo

 

Copyright | Ayuda | Mapa